Trialjectory, an AI-powered decision-support platform for patients, health-care providers and pharma, has raised $20 million in a Series A round led by New York-based global private equity and venture capital firm Insight Partners, with participation from new investor JAL Ventures and from existing investors Contour Venture Partners, Rho Capital and TIA Ventures.

TrialJectory is an AI-based clinical trial-matching platform that uses self-reported clinical information to facilitate the clinical trial search and enrollment by cancer patients and their physicians. The Company partners with all sectors of the health industry to revolutionize the trial recruitment process, leading to reduced operational costs and expedited drugs' time to market.